Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03587194 · ClinicalTrials.gov registry record · Phase 4
Evaluation of Add on Enstilar in Patients Using Otezla for Psoriasis
A Phase 4 study, sponsored by Psoriasis Treatment Center of Central New Jersey.
- Completed
- Registry status
- Phase 4
- Development phase
- 50
- Enrollment target
NCT03587194: Completed Phase 4 study, sponsored by Psoriasis Treatment Center of Central New Jersey.
NCT03587194 is a Phase 4 study that has completed, run by Psoriasis Treatment Center of Central New Jersey. The registered enrollment target is 50 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03587194, a Phase 4 study, has completed, sponsored by Psoriasis Treatment Center of Central New Jersey.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 50 participants
- Enrollment target
Study Summary
Add-on Enstilar to Otezla therapy.
Primary Outcome
Patients who achieve Psoriasis Area Severity Index 75 at week 12. PASI scores range 0-72 (maximal disease)
Interventions
- DRUG Otezla
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2018-07-23 |
| Est. Completion | 2019-07-01 |
| Phase | Phase 4 |
What the finished NCT03587194 record still lists
NCT03587194 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 1 intervention - of which Otezla is the first listed.
NCT03587194 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03587194 about?
NCT03587194 is a clinical study titled "Evaluation of Add on Enstilar in Patients Using Otezla for Psoriasis". Add-on Enstilar to Otezla therapy.
What is the current status of trial NCT03587194?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 50 participants. The study started on 2018-07-23. Estimated completion is 2019-07-01.
What interventions are being tested in trial NCT03587194?
The interventions under investigation include: Otezla (DRUG).
Who is sponsoring clinical trial NCT03587194?
This trial is sponsored by Psoriasis Treatment Center of Central New Jersey, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03587194's enrollment target sits among peer trials
50 1255th of 2000 higher than 678 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI